A Phase II Study of Single Agent Depsipeptide (FK228) in Radioiodine (RAI)-Refractory Metastatic Non-Medullary (Papillary, Follicular, and Hurthle Cell Variants) Thyroid Carcinoma

Trial Profile

A Phase II Study of Single Agent Depsipeptide (FK228) in Radioiodine (RAI)-Refractory Metastatic Non-Medullary (Papillary, Follicular, and Hurthle Cell Variants) Thyroid Carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2013

At a glance

  • Drugs Romidepsin (Primary)
  • Indications Thyroid cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Jul 2012 Actual end date (1 Jul 2012) added as reported by ClinicalTrials.gov.
    • 06 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Aug 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top